Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 7.00 thousand shares for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-03
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 5.00K shares, a 87.18% decline year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 2.00K shares, a 0.00% change year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 32.00K shares, a 3100.00% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 132.00K shares, a 13.79% increase from fiscal 2024.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 116.00K shares, a 46.30% decline from fiscal 2023.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 216.00K shares, a 34.16% increase from fiscal 2022.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 161.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | 5.00K shares derived: sum of 2 quarters · filed 2026-08-03 | 7.00K shares 10-Q · filed 2026-08-03 | 39.00K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 0.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-05-04 | 2.00K shares 10-Q · filed 2026-05-04 | 34.00K shares derived: sum of 3 quarters · filed 2026-05-04 | 73.00K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 2.00K shares 10-Q/A · filed 2026-02-26 | 34.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 73.00K shares derived: sum of 3 quarters · filed 2026-02-26 | 132.00K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-09-30 | 32.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | 71.00K shares derived: sum of 2 quarters · filed 2025-11-17 | 130.00K shares derived: sum of 3 quarters · filed 2025-11-17 | 132.00K shares 10-K · filed 2025-11-17 |
| 2025-06-30 | 39.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-04 | 98.00K shares derived: sum of 2 quarters · filed 2025-08-04 | 100.00K shares 10-Q · filed 2025-08-04 | 101.00K shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 59.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-05 | 61.00K shares 10-Q · filed 2025-05-05 | 62.00K shares derived: sum of 3 quarters · filed 2025-05-05 | 70.00K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 2.00K shares 10-Q · filed 2025-02-03 | 3.00K shares derived: sum of 2 quarters · filed 2025-02-03 | 11.00K shares derived: sum of 3 quarters · filed 2025-02-03 | 33.00K shares derived: sum of 4 quarters · filed 2025-02-03 |
| 2024-09-30 | 1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | 9.00K shares derived: sum of 2 quarters · filed 2024-11-18 | 31.00K shares derived: sum of 3 quarters · filed 2024-11-18 | 116.00K shares 10-K · filed 2024-11-18 |
| 2024-06-30 | 8.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-02 | 30.00K shares derived: sum of 2 quarters · filed 2024-08-02 | 115.00K shares 10-Q · filed 2024-08-02 | 214.00K shares derived: sum of 4 quarters · filed 2024-08-02 |
| 2024-03-31 | 22.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-02 | 107.00K shares 10-Q · filed 2024-05-02 | 206.00K shares derived: sum of 3 quarters · filed 2024-05-02 | 252.00K shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 85.00K shares 10-Q · filed 2024-02-02 | 184.00K shares derived: sum of 2 quarters · filed 2024-02-02 | 230.00K shares derived: sum of 3 quarters · filed 2024-02-02 | 264.00K shares derived: sum of 4 quarters · filed 2024-02-02 |
| 2023-09-30 | 99.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | 145.00K shares derived: sum of 2 quarters · filed 2023-11-21 | 179.00K shares derived: sum of 3 quarters · filed 2023-11-21 | 216.00K shares 10-K · filed 2023-11-21 |
| 2023-06-30 | 46.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | 80.00K shares derived: sum of 2 quarters · filed 2023-08-07 | 117.00K shares 10-Q · filed 2023-08-07 | 143.00K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 34.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | 71.00K shares 10-Q · filed 2023-05-08 | 97.00K shares derived: sum of 3 quarters · filed 2023-06-05 | |
| 2022-12-31 | 37.00K shares 10-Q · filed 2023-02-07 | 63.00K shares derived: sum of 2 quarters · filed 2023-06-05 | ||
| 2022-09-30 | 26.00K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | 161.00K shares 10-K/A · filed 2023-06-05 | ||
| 2022-06-30 | 135.00K shares 10-Q · filed 2022-08-08 | |||
| 2019-09-30 | -16.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-13 | 284.62K shares derived: sum of 2 quarters · filed 2019-12-13 | 314.32K shares derived: sum of 3 quarters · filed 2019-12-13 | 324.46K shares 10-K · filed 2019-12-13 |
| 2019-06-30 | 301.06K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | 330.76K shares derived: sum of 2 quarters · filed 2019-08-09 | 340.90K shares 10-Q · filed 2019-08-09 | |
| 2019-03-31 | 29.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-02 | 39.84K shares 10-Q · filed 2019-05-02 | ||
| 2018-12-31 | 10.14K shares 10-Q · filed 2019-02-11 | |||
| 2018-09-30 | 187.69K shares 10-K · filed 2019-12-13 | |||
| 2017-09-30 | 38.38K shares 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |